Last reviewed · How we verify
NCT05993533: QuantiXa
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
trial in Venous Thromboembolic Disease in 100 participants. Status unknown.
22 December 2023
Quick facts
| Lead sponsor | Direction Centrale du Service de Santé des Armées |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 22 June 2023 |
| Primary completion | 22 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across France |
Conditions studied
- Venous Thromboembolic Disease — all drugs for Venous Thromboembolic Disease →
Sponsor
Direction Centrale du Service de Santé des Armées — full company profile →
Who can join
Adults 18 to 65, any sex, with Venous Thromboembolic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Quantra(r) hemostasis analyzer (Stago) is a recent addition to the family of global hemostasis tests. It uses ultrasound-based technology to characterize the viscoelastic properties of a whole blood sample during coagulation. The Qplus(r) cartridge consists of independent channels, each containing different reagents that provide parallel measurements of 6 parameters. This global test takes into account cellular elements such as platelets and red blood cells in clot formation, and also explores fibrinolysis. In addition, this test is of particular interest in delocalized biology, i.e. at the patient's bedside, and avoids the time-consuming laboratory centrifugation stage required for routine analyzers. In practice, this test has been developed to monitor haemostasis in patients who may present with a range of coagulopathies of various etiologies, but also in the management of haemorrhagic patients, in order to adapt the administration of blood products in particular. The Quantra (r) analyzer could therefore be of interest since it could be deployed in overseas operations to manage war casualties. Recent studies (EACTAIC-ICCVA congress, October 2021) have shown that there is a good correlation between anti-Xa activity and the CTR (coagulation time ratio) parameter of the Quantra cartridge Qplus (TM), suggesting that this automated system could be used to manage anticoagulant therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05993533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Venous Thromboembolic Disease
Currently open trials in the same condition.
- NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
- NCT07270263 — Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies · NA · recruiting
- NCT06232551 — Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism · NA · recruiting
- NCT05396157 — Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study · active not recruiting
- NCT07016542 — Cohort for Monitoring Patients With Venous Thromboembolic Disease · recruiting
Other Direction Centrale du Service de Santé des Armées trials
Trials by the same sponsor.
- NCT07352904 — Exploration Strategies in Night Vision Sensors · not yet recruiting
- NCT07344493 — Average ANKLE GO Score in the Objective Functional Assessment of the Ankle in Healthy Military Personnel (ANKMIL) · completed
- NCT06996275 — Attachment and Post-Traumatic Stress Disorder in Military Personnel: Characterization of the French Military Population, · not yet recruiting
- NCT06490029 — Diagnostic of Various Ototoxicity Induced by Cancer Treatment · recruiting
- NCT06174181 — Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degenerat · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05993533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Direction Centrale du Service de Santé des Armées
- Last refreshed: 15 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05993533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing